Contact
searchSearch
HMP Global
Login

Acute Myeloid Leukemia

Acute Myeloid Leukemia
Excellence Forum
Leaders in the field sharing authoritative insights and institutional best practices.

Eunice Wang, MD, and Eytan Stein, MD
Videos
Menin Inhibitors Advance Targeted Treatment Strategies in NPM1-Mutated and KMT2A-Rearranged Acute Myeloid Leukemia
10/24/2026
Eytan Stein, MD; Eunice S. Wang
Eunice Wang, MD, and Eytan Stein, MD, discuss advances in menin inhibitor therapy for acute myeloid leukemia, highlighting the clinical activity of revumenib and ziftomenib, emerging combination strategies, mechanisms of acquired resistance,...
Eunice Wang, MD, and Eytan Stein, MD, discuss advances in menin inhibitor therapy for acute myeloid leukemia, highlighting the clinical activity of revumenib and ziftomenib, emerging combination strategies, mechanisms of acquired resistance,...
Eunice Wang, MD, and Eytan...
10/24/2026
Oncology
Pinkal Desai, MD
Videos
MRD-Guided Risk Stratification Refines Transplant Decisions in Patients With Acute Myeloid Leukemia
10/24/2026
Pinkal Desai, MD
Pinkal Desai, MD, discusses post-remission treatment strategies in acute myeloid leukemia, highlighting how molecular risk classification, measurable residual disease monitoring, and transplant-related risk guide allogenic stem cell...
Pinkal Desai, MD, discusses post-remission treatment strategies in acute myeloid leukemia, highlighting how molecular risk classification, measurable residual disease monitoring, and transplant-related risk guide allogenic stem cell...
Pinkal Desai, MD, discusses...
10/24/2026
Oncology
Gail Roboz, MD
Videos
All-Oral Treatment Strategy May Reduce Treatment Burden in Acute Myeloid Leukemia
10/14/2026
Gail Roboz, MD
Gail Roboz, MD, discusses results from the phase 1/2 ASCERTAIN-V trial evaluating all-oral decitabine and cedazuridine plus venetoclax in patients with acute myeloid leukemia ineligible for intensive chemotherapy, highlighting encouraging...
Gail Roboz, MD, discusses results from the phase 1/2 ASCERTAIN-V trial evaluating all-oral decitabine and cedazuridine plus venetoclax in patients with acute myeloid leukemia ineligible for intensive chemotherapy, highlighting encouraging...
Gail Roboz, MD, discusses...
10/14/2026
Oncology
Ira Zackon, MD
Videos
Real-World Analysis Finds Venetoclax-Based Induction Effective for Very Elderly Patients With Acute Myeloid Leukemia
03/02/2026
Ira Zackon, MD
Ira Zackon, MD, shared results from a large real-world analysis which found venetoclax plus a hypomethylating agent is a feasible and effective therapeutic option for patients with AML aged 70 years and older.
Ira Zackon, MD, shared results from a large real-world analysis which found venetoclax plus a hypomethylating agent is a feasible and effective therapeutic option for patients with AML aged 70 years and older.
Ira Zackon, MD, shared results...
03/02/2026
Oncology
Ibrahim Aldoss, MD
Videos
Azacitidine Plus Venetoclax Shows Superior Efficacy Compared With Intensive Chemotherapy for Newly Diagnosed Acute Myeloid Leukemia
01/12/2026
Ibrahim Aldoss, MD
Ibrahim Aldoss, MD, shared results from the phase 2 PARADIGM trial which showed frontline azacitidine plus venetoclax significantly improved survival, response rates, and quality of life compared with intensive chemotherapy for AML.
Ibrahim Aldoss, MD, shared results from the phase 2 PARADIGM trial which showed frontline azacitidine plus venetoclax significantly improved survival, response rates, and quality of life compared with intensive chemotherapy for AML.
Ibrahim Aldoss, MD, shared...
01/12/2026
Oncology
Amer Zeidan, MBBS, MHS
Videos
Ziftomenib Plus Standard Induction Therapy Demonstrates Meaningful Clinical Activity for Patients With AML: KOMET-007
08/25/2025
Amer Zeidan, MBBS
At the EHA 2025 Congress, Amer Zeidan, MBBS, MHS, shared results from the KOMET-007 trial which evaluated the efficacy of ziftomenib combined with standard induction therapy for patients with newly diagnosed acute myeloid leukemia.
At the EHA 2025 Congress, Amer Zeidan, MBBS, MHS, shared results from the KOMET-007 trial which evaluated the efficacy of ziftomenib combined with standard induction therapy for patients with newly diagnosed acute myeloid leukemia.
At the EHA 2025 Congress, Amer...
08/25/2025
Oncology
Amer Zeidan, MBBS, MHS
Videos
Decitabine-Cedazuridine Plus Venetoclax Therapy Shows Efficacy and Safety for Patients With Newly Diagnosed AML
08/20/2025
Amer Zeidan, MBBS
Amer Zeidan, MBBS, MHS, shares results from a phase 2 trial determining the safety and efficacy of decitabine-cedazuridine plus venetoclax for patients with newly diagnosed acute myeloid leukemia ineligible for induction chemotherapy.
Amer Zeidan, MBBS, MHS, shares results from a phase 2 trial determining the safety and efficacy of decitabine-cedazuridine plus venetoclax for patients with newly diagnosed acute myeloid leukemia ineligible for induction chemotherapy.
Amer Zeidan, MBBS, MHS, shares...
08/20/2025
Oncology
Naval Daver, MD
Conference Coverage
Challenges of Applying MRD Decision-Making to Determine Transplant Among Patients With AML
08/05/2025
Naval G. Daver
At the 2025 Great Debates in Hematologic Malignancies meeting, Naval Daver, MD, debates against minimal residual disease negativity as the predominate determining factor for transplant eligibility among patients with acute myeloid leukemia.
At the 2025 Great Debates in Hematologic Malignancies meeting, Naval Daver, MD, debates against minimal residual disease negativity as the predominate determining factor for transplant eligibility among patients with acute myeloid leukemia.
At the 2025 Great Debates in...
08/05/2025
Oncology
Aaron Goldberg, MD, PhD
Conference Coverage
Optimizing Targeted and Genetic Therapeutic Strategies for Patients With R/R Acute Myeloid Leukemia
08/05/2025
At the 2025 Great Debates in Hematologic Malignancies meeting, Aaron Goldberg, MD, PhD, discussed evolving treatment strategies and therapies for patients with relapsed/ refractory acute myeloid leukemia.
At the 2025 Great Debates in Hematologic Malignancies meeting, Aaron Goldberg, MD, PhD, discussed evolving treatment strategies and therapies for patients with relapsed/ refractory acute myeloid leukemia.
At the 2025 Great Debates in...
08/05/2025
Oncology
Andrew Artz, MD, MS
Conference Coverage
Benefits of Utilizing MRD Negativity to Determine Transplant Eligibility for Patients With AML
08/05/2025
Andrew Artz, MD, MS, participated in a debate arguing for the benefits of utilizing minimal residual disease negativity as the primary marker for transplantation eligibility among patients with acute myeloid leukemia at the 2025 Great Debates...
Andrew Artz, MD, MS, participated in a debate arguing for the benefits of utilizing minimal residual disease negativity as the primary marker for transplantation eligibility among patients with acute myeloid leukemia at the 2025 Great Debates...
Andrew Artz, MD, MS,...
08/05/2025
Oncology

Recent News

FDA Approval
FDA Approves Amivantamab and Hyaluronidase for Previously Treated Head and Neck Squamous Cell Carcinoma
11/06/2026
Stephanie Holland
Results from the phase 1b/2 OrigAMI-4 trial supported FDA accelerated approval of subcutaneous amivantamab and hyaluronidase for previously treated recurrent or metastatic head and neck squamous cell carcinoma, introducing a dual...
Results from the phase 1b/2 OrigAMI-4 trial supported FDA accelerated approval of subcutaneous amivantamab and hyaluronidase for previously treated recurrent or metastatic head and neck squamous cell carcinoma, introducing a dual...
Results from the phase 1b/2...
11/06/2026
Oncology
News
Varegacestat Advances Toward European Approval for Desmoid Tumors Following RINGSIDE Survival Benefit
11/05/2026
Emily Estrada
Based on results from the phase 3 RINGSIDE trial, the European Medicines Agency has validated the marketing authorization application for varegacestat in adults with desmoid tumors, following significant improvements in progression-free...
Based on results from the phase 3 RINGSIDE trial, the European Medicines Agency has validated the marketing authorization application for varegacestat in adults with desmoid tumors, following significant improvements in progression-free...
Based on results from the phase...
11/05/2026
Oncology
News
Lirafugratinib Receives NCCN Category 2A Recommendation Following FDA Approval in FGFR2-Altered Cholangiocarcinoma
11/05/2026
Emily Estrada
Following FDA approval supported by the phase 1/2 ReFocus trial, lirafugratinib has been added to the NCCN Guidelines as a Category 2A preferred subsequent-line treatment option for patients with cholangiocarcinoma harboring FGFR2 fusions or...
Following FDA approval supported by the phase 1/2 ReFocus trial, lirafugratinib has been added to the NCCN Guidelines as a Category 2A preferred subsequent-line treatment option for patients with cholangiocarcinoma harboring FGFR2 fusions or...
Following FDA approval supported...
11/05/2026
Oncology
News
Pumitamig Plus Chemotherapy Shows Antitumor Activity Regardless of Brain Metastasis Status
11/04/2026
Emily Estrada
Results from two phase 2 trials demonstrated encouraging intracranial responses with pumitamig plus chemotherapy in patients with small cell lung cancer and triple-negative breast cancer with brain metastases, supporting further investigation...
Results from two phase 2 trials demonstrated encouraging intracranial responses with pumitamig plus chemotherapy in patients with small cell lung cancer and triple-negative breast cancer with brain metastases, supporting further investigation...
Results from two phase 2 trials...
11/04/2026
Oncology
News
SEZ6-Targeted Antibody-Drug Conjugate ABBV-706 Demonstrates Promising Antitumor Activity in Relapsed or Refractory Small Cell Lung Cancer
11/04/2026
Emily Estrada
Updated phase 1 results demonstrated promising antitumor activity with the SEZ6-targeted antibody-drug conjugate ABBV-706 in relapsed or refractory small cell lung cancer, with encouraging response and survival outcomes alongside exploratory...
Updated phase 1 results demonstrated promising antitumor activity with the SEZ6-targeted antibody-drug conjugate ABBV-706 in relapsed or refractory small cell lung cancer, with encouraging response and survival outcomes alongside exploratory...
Updated phase 1 results...
11/04/2026
Oncology
News
Phase 1 Trial Shows 70% Response Rate With SKB500 in Heavily Pretreated Patients With Small Cell Lung Cancer
11/04/2026
Emily Estrada
Updated results from a phase 1 trial demonstrated promising antitumor activity with the B7-H3-directed antibody-drug conjugate SKB500 in heavily pretreated patients with small cell lung cancer, with the lower dose showing more favorable...
Updated results from a phase 1 trial demonstrated promising antitumor activity with the B7-H3-directed antibody-drug conjugate SKB500 in heavily pretreated patients with small cell lung cancer, with the lower dose showing more favorable...
Updated results from a phase 1...
11/04/2026
Oncology
News
Varegacestat Significantly Improves Pain, Physical Function, and Quality of Life in Patients With Desmoid Tumors
11/04/2026
Emily Estrada
Results from RINGSIDE trial demonstrated rapid and sustained improvements in patient-reported pain, desmoid-related symptoms, physical function, and quality of life with varegacestat compared with placebo in patients with progressing desmoid...
Results from RINGSIDE trial demonstrated rapid and sustained improvements in patient-reported pain, desmoid-related symptoms, physical function, and quality of life with varegacestat compared with placebo in patients with progressing desmoid...
Results from RINGSIDE trial...
11/04/2026
Oncology
FDA Alerts
Zanubrutinib Combination Receives FDA Priority Review Following Positive Phase 3 MANGROVE Results
11/04/2026
Stephanie Holland
Results from the phase 3 MANGROVE trial supported FDA Priority Review of zanubrutinib plus rituximab for previously untreated mantle cell lymphoma, following a significant progression-free survival benefit compared with bendamustine plus...
Results from the phase 3 MANGROVE trial supported FDA Priority Review of zanubrutinib plus rituximab for previously untreated mantle cell lymphoma, following a significant progression-free survival benefit compared with bendamustine plus...
Results from the phase 3...
11/04/2026
Oncology
News
Medicare Expands Coverage of Signatera MRD Testing for Hepatocellular Carcinoma Surveillance
11/03/2026
Stephanie Holland
Medicare coverage has been extended to serial Signatera molecular residual disease testing for surveillance of patients with early-stage hepatocellular carcinoma who have no evidence of disease following surgery, supported by real-world...
Medicare coverage has been extended to serial Signatera molecular residual disease testing for surveillance of patients with early-stage hepatocellular carcinoma who have no evidence of disease following surgery, supported by real-world...
Medicare coverage has been...
11/03/2026
Oncology
News
What to Expect at the 2026 NANETS Multidisciplinary NET Medical Symposium
11/02/2026
Janelle Bradley
The 2026 NANETS Multidisciplinary NET Medical Symposium will spotlight emerging research, evolving treatment strategies, and practical insights to advance neuroendocrine tumor care.
The 2026 NANETS Multidisciplinary NET Medical Symposium will spotlight emerging research, evolving treatment strategies, and practical insights to advance neuroendocrine tumor care.
The 2026 NANETS...
11/02/2026
Oncology

HMP Global Products

Events

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2026 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Terms of Use